Guardant Health announces positive results from pivotal ECLIPSE study evaluating a blood test for the detection of colorectal cancer

• The test demonstrated 83% sensitivity for the detection of colorectal cancer with specificity of 90%
• Results pave the way for first potential FDA-approved and Medicare-reimbursed blood test for colorectal cancer screening
• The company will host a webcast and conference call to discuss the results today at 5:00 p.m. ET, 2:00 p.m. PT

Excerpt from the Press Release:

PALO ALTO, Calif.–(BUSINESS WIRE)–Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced today positive results from ECLIPSE (Evaluation of ctDNA LUNAR Assay In an Average Patient Screening Episode), an over 20,000 patient registrational study evaluating the performance of its blood test for detecting colorectal cancer (CRC) in average-risk adults.

The test demonstrated 83% sensitivity in detecting individuals with CRC. Specificity was 90% in both individuals without advanced neoplasia and in those who had a negative colonoscopy result. This test also demonstrated 13% sensitivity in detecting advanced adenomas. Based on these study results, Guardant Health plans to complete its premarket approval submission to the U.S. Food and Drug Administration (FDA) in the first quarter of 2023. These results exceed the performance criteria set forth by the Centers for Medicare & Medicaid Services (CMS) for reimbursement.¹

In this study, two configurations of a multimodal blood-based screening test were evaluated independently – a cell-free DNA (cfDNA)-only test and a cfDNA test with protein biomarkers.

Click the button below to read the entire Press Release:

Continue Reading The Press Release